

February 04, 2020

BSE Limited

The Corporate Relationship Department
P.J. Towers,
Dalal Street,
Mumbai - 400001

Through: BSE Listing Centre

Scrip Code: 540788

Dear Sir/ Madam,

Sub: Outcome of meeting of the Board of Directors of Aspira Pathlab & Diagnostics Limited, pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Schedule III to the listing Regulations, we wish to inform you that the Board of Directors of the Company at its meeting held today has approved the unaudited Financial Results for third quarter and nine months ended December 31, 2019.

The above financial Results along with the Limited Review Report on the Financial Results are enclosed herewith.

The meeting of the Board of Directors was concluded at 5.30 p.m.

Kindly take the same on your records.

Thanking you.

Yours faithfully,

For **ASPIRA PATHLAB & DIAGNOSTIC LIMITED**



Mamta Mav

Company Secretary



Aspira Pathlab & Diagnostics Limited

(CIN L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shradhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai -400086

Unaudited Financial Results for the Quarter/Nine Months ended 31st December, 2019

(Rs. in Lakhs)

Particulars	Quarter ended			Nine Months ended		Year ended
	31-Dec-19 (Unaudited)	30-Sep-19 (Unaudited)	31-Dec-18 (Unaudited)	31-Dec-19 (Unaudited)	31-Dec-18 (Unaudited)	31-Mar-19 (Audited)
1. Income						
(a) Revenue from Operations						
Sales/Income from Operations	221.98	232.54	208.06	644.84	556.01	763.71
Other Operating Income						
(b) Other Income	7.15	7.43	7.18	21.91	17.79	25.32
Total income	229.13	239.96	215.24	666.74	573.80	789.03
2. Expenses						
(a) Cost of Materials consumed	52.72	44.63	72.66	149.97	153.87	225.59
(b) Purchase of stock-in-trade	-	-	-	-	-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
(d) Employee benefits expense	126.87	120.21	115.28	358.16	328.25	447.36
(e) Finance Costs	27.71	24.08	16.14	76.58	70.50	96.07
(f) Depreciation and amortisation expense	43.13	40.63	31.00	123.98	91.16	122.84
(g) Other expenses	80.62	96.44	103.40	250.72	323.92	415.47
Total Expenses	331.04	325.99	338.48	959.42	967.70	1,307.32
3. Profit / (Loss) before exceptional items and tax (1-2)	(101.91)	(86.02)	(123.24)	(292.67)	(393.90)	(518.29)
4. Exceptional Items						
5. Profit / (Loss) before tax (3+4)	(101.91)	(86.02)	(123.24)	(292.67)	(393.90)	(518.29)
6. Tax Expenses						
7. Profit / (Loss) after tax (5-6)	(101.91)	(86.02)	(123.24)	(292.67)	(393.90)	(518.29)
8. Other Comprehensive income (net of tax)						0.97
9. Total Comprehensive income (7+8)	(101.91)	(86.02)	(123.24)	(292.67)	(393.90)	(517.32)
10. Paid up Equity share capital (face value 10 each)	929.30	819.30	819.30	929.30	819.30	819.30
11. Earning per share						
(a) Basic	(1.10)	(1.05)	(1.50)	(3.15)	(4.81)	(6.31)
(b) Diluted	(1.18)	(1.05)	(1.50)	(3.51)	(4.10)	(1.78)

Notes

- The previous period figures have been regrouped wherever necessary.
- The above result of the company have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 04th February 2020. The Statutory auditors of the Company have carried out a limited review of above results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.
- The unaudited standalone financial results of the company have been prepared in accordance with Indian Accounting standards (Ind AS) prescribed under Section 133 of the Companies Act 2013 read with Companies (Indian Accounting Standard) Rules, 2015, as amended.

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

PSH
Name : Dr. Pankaj Shah
Designation : Managing Director
DIN-02836324



Place : Mumbai
Date : 04.02.2020



P KHETAN & CO
Chartered Accountants

19B B BGanguly Street
Room No. 5, 2nd Floor
Kolkata – 700012
Phone- 033-40734009
Mobile- 9883093350
e-mail- khetanpk@gmail.com

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Aspira Pathlab & Diagnostics Limited

We have reviewed the accompanying statement of Unaudited Standalone Financial Results of Aspira Pathlab & Diagnostics Limited for the quarter and nine months ended December 31, 2019 ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("the Regulation") as amended.

This statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P Khetan & Co
Chartered Accountant

Pankaj Khetan

(Pankaj Kumar Khetan)
Partner

M.No- 066080

Firm Reg. No- 327386E

Place- Kolkata

Date- 04.02.2020

UDIN: 20066080AAAAAC7513

